you are here: Home News Dr Reddys Lab

Dr Reddys Lab

Cash Trade | Price for Dr Reddy's Lab is breaking out of downsloping wedge pattern
Dr Reddy's Lab recalls over 4,000 bottles of generic drug in US
Indian pharmaceutical industry to touch $130 billion by 2030: Dr Reddy's chairman K Satish Reddy
Dr Reddy's signs licensing pact with Eli Lilly to produce COVID-19 treatment drug Baricitinib
Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan
Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities
Dr Reddy's Lab shares fall 4% after firm shuts plants on reports of data breach
Hold Dr. Reddy's Lab; target of Rs 5325: Emkay Global Financial
Divi’s Labs an outlier in the pharma sector
5 reasons why Nomura downgraded Indian equities to ‘neutral’
Dr. Reddy’s Lab Q3 PAT seen up 60.6% YoY to Rs. 472.4 cr: Sharekhan
Dr. Reddy’s Lab Q2 PAT seen up 20.2% YoY to Rs. 356.1 cr: Sharekhan
Automobile, pharma firms big beneficiaries of export incentive scheme
Hold Dr Reddy's Lab; target of Rs 2000: Centrum Research
Dr. Reddy’s Lab Q4 PAT may dip 17.7% YoY to Rs. 269.4 cr: KR Choksey
India Inc pay gap: CEOs earn up to 1,200-times of average staff
Indian ADRs: ICICI, HDFC Bank, Tata Motors rally
Indian ADRs: ICICI, HDFC Bank, Infosys rally
Indian ADRs: Tata Motors & Dr Reddy's gain, HDFC Bank falls
Indian ADRs: ICICI & HDFC Bank gain, Dr Reddy's falls
Indian ADRs: Dr Reddy's Labs, HDFC Bank rally 3%
Indian ADRs: Infosys, Tata Motors, Dr Reddy's Labs decline
Indian ADRs: Wipro slips 1.7%, Dr Reddy's Labs rises 1%
Indian ADRs: Tata Motors falls 2%, Infosys slips 1%
Indian ADRs: Infosys & Wipro decline, ICICI Bank gains

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Dr Reddys Lab

Cash Trade | Price for Dr Reddy's Lab is breaking out of downsloping wedge pattern

Dr Reddy's Lab recalls over 4,000 bottles of generic drug in US

Indian pharmaceutical industry to touch $130 billion by 2030: Dr Reddy's chairman K Satish Reddy

Dr Reddy's signs licensing pact with Eli Lilly to produce COVID-19 treatment drug Baricitinib

Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan

Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities

Dr Reddy's Lab shares fall 4% after firm shuts plants on reports of data breach

Hold Dr. Reddy's Lab; target of Rs 5325: Emkay Global Financial

Divi’s Labs an outlier in the pharma sector

5 reasons why Nomura downgraded Indian equities to ‘neutral’

Dr. Reddy’s Lab Q3 PAT seen up 60.6% YoY to Rs. 472.4 cr: Sharekhan

Dr. Reddy’s Lab Q2 PAT seen up 20.2% YoY to Rs. 356.1 cr: Sharekhan

Automobile, pharma firms big beneficiaries of export incentive scheme

Hold Dr Reddy's Lab; target of Rs 2000: Centrum Research

Dr. Reddy’s Lab Q4 PAT may dip 17.7% YoY to Rs. 269.4 cr: KR Choksey

India Inc pay gap: CEOs earn up to 1,200-times of average staff

Indian ADRs: ICICI, HDFC Bank, Tata Motors rally

Indian ADRs: ICICI, HDFC Bank, Infosys rally

Indian ADRs: Tata Motors & Dr Reddy's gain, HDFC Bank falls

Indian ADRs: ICICI & HDFC Bank gain, Dr Reddy's falls

Indian ADRs: Dr Reddy's Labs, HDFC Bank rally 3%

Indian ADRs: Infosys, Tata Motors, Dr Reddy's Labs decline

Indian ADRs: Wipro slips 1.7%, Dr Reddy's Labs rises 1%

Indian ADRs: Tata Motors falls 2%, Infosys slips 1%

Indian ADRs: Infosys & Wipro decline, ICICI Bank gains